Dr. Mazdak Asadian-Birjand

Dr. Mazdak Asadian-Birjand has extensive work experience in the field of chemistry and biomedical research. Dr. Mazdak is currently working as a Principal Scientist in Chemistry at Sapreme Technologies BV since April 2021. In this role, they are responsible for developing platform technologies for cytosolic delivery of macromolecular therapeutics for cancer treatment. Dr. Mazdak has led efforts to develop a next-generation drug conjugate platform and has collaborated with external companies to advance the technology. Dr. Mazdak is also the Project Leader for multiple Endoscape® technology-driven projects and has filed 4 patents.

Prior to Sapreme Technologies, Dr. Asadian-Birjand worked at Charité - University Medicine Berlin as a Laboratory Manager and a Postdoctoral Research Fellow from April 2017 to March 2019. In these roles, they designed and developed conjugation strategies for macromolecular therapeutics and optimized the efficacy of various antibody drug conjugates, immunotoxins, and non-viral gene delivery vectors. Dr. Mazdak also supervised and trained graduate and undergraduate students and filed 2 patents.

Before that, they worked as a Research Fellow and a Research Assistant at Freie University Berlin, Division of Organic Chemistry. In their role as a Research Fellow from July 2011 to October 2015, they developed targeted and magnetic nanoparticles for capturing circulating tumor cells from patient's blood samples. As a Research Assistant from January 2011 to June 2011, they assisted Prof. Marcelo Calderon and Prof. Rainer Haag in their research.

Dr. Asadian-Birjand also has research assistant experience at Centro de Investigación Príncipe Felipe (CIPF) and Universidad Nacional de Cordoba. Dr. Mazdak worked at Centro de Investigación Príncipe Felipe (CIPF) from February 2013 to March 2013 and at Universidad Nacional de Cordoba in November 2012. Additionally, they worked as a Research Assistant at Fraunhofer IZM Berlin from June 2008 to December 2010 and at celares GmbH from July 2010 to September 2010.

Overall, Dr. Mazdak Asadian-Birjand has demonstrated a strong background in chemistry and biomedical research, with a focus on developing innovative technologies for cancer treatment.

Dr. Mazdak Asadian-Birjand completed their education in Organic Chemistry at Freie Universität Berlin. From 2009 to 2011, they earned a Master's Degree in Chemistry from the same institution. Following that, they pursued further studies and obtained a Dr. rer. nat. degree in Organic Chemistry from Freie Universität Berlin, which they completed in 2015.